Virtual populations.
Real decisions.

Specialists in modelling non-communicable diseases

Tackling population health challenges means asking big questions, such as:

What impact will the increasing burden of chronic kidney disease have on healthcare costs over the next 20 years?
How can you look 10 to 20 years ahead to understand the impact of a new drug on its users and your revenue stream?
How do you determine whether it is clinically and financially feasible to progress a drug from Phase II to Phase III clinical trials?
What would be the health and economic benefits of earlier screening for the diagnosis and treatment of conditions such as chronic kidney disease or liver disease?
How can you boost a nation’s health with targeted help at different life stages?

And how do you even know which are the right questions to ask?

That’s where we can help.

Helping you make the best decisions

Our simulation and analysis expertise turns tomorrow’s population health questions and challenges into today’s focussed, specific, actionable decisions.

We can help you understand and explore those questions and challenges far into the future. Our scenario modelling will show you how different kinds of health interventions, drug innovations and policy changes can impact them.

And that will help you choose the best way forward.

Why Us?

Deep expertise in modelling non-communicable diseases, combined with entrepreneurial vision.

Why Us?

How do we do it?

We’ve created a specific process to help you find, ask and answer the right questions.

Method

What have we done?

We’ve answered many different kinds of questions for many different organisations in over 70 countries.

Track Record

Why choose us?

We have an experienced and multi-disciplinary team of software engineers, population health and policy research experts, and mathematicians.

Team

HealthLumen Blog

Join us at upcoming conferences to discuss the latest findings in the epidemiology of rare diseases.

It’s a well-established truism that rare diseases, whilst rare at the individual disease level, are collectively quite common, with some 300 million people worldwide living with a rare disease. However, are rare diseases actually as rare at the individual disease level as current estimates suggest  – what could be the extent of the “hidden population”? […]

Read

NEWS: Policy interventions could reduce chronic liver disease and liver cancer in Europe by up to 7% by 2030 

Europe has the largest burden of diagnosed liver disease globally with almost 30 million people in the European Union alone estimated to be living with a chronic liver condition. Liver cirrhosis accounts for 1.8% of all deaths reported in Europe (170,000 deaths annually) with a 100% increase in cirrhosis deaths observed across the Eastern European […]

Read

NEWS: Innovate UK-funded study reveals cost of air pollution related disease to local populations

Sandwell Metropolitan Borough Council has announced the successful completion of a groundbreaking pilot study on reducing poor air quality through community measures. The pilot study was launched in November 2022 by a consortium led by Enjoy the Air in partnership with Sandwell Metropolitan Borough Council to examine the link between air pollution, behaviour and the […]

Read

Estimating the prevalence and future burden of rare genetic diseases: challenges and solutions

Genetic diseases are conditions caused by abnormalities in an individual’s DNA. They can be inherited from one or both parents, or can occur as a result of spontaneous genetic mutations. They may be caused by a mutation in a single gene (monogenic); by a chromosomal change where there are more or fewer copies than usual; […]

Read